Vifor (International) AG
Cross-sectional Study to Assess Prevalence and Burden of CKD-associated Pruritus in Hemodialysis Patients
- Conditions
- Chronic Kidney Disease-associated Pruritus
- First Posted Date
- 2022-11-23
- Last Posted Date
- 2023-07-05
- Lead Sponsor
- Vifor (International) Inc.
- Registration Number
- NCT05625542
Cross-sectional Study to Assess Prevalence and Burden of CKD-associated Pruritus in Haemodialysis Patients
- Conditions
- Chronic Kidney Disease-associated Pruritus
- First Posted Date
- 2022-09-01
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Vifor (International) Inc.
- Target Recruit Count
- 3100
- Registration Number
- NCT05524467
- Locations
- 🇪🇸
3011, Barcelona, Spain
🇮🇹4005, Lecce, Italy
🇮🇹4018, Milano, Italy
RAYALDEE Non Interventional Study (NIS) on Effectiveness in ND-CKD SHPT Patients
- Conditions
- Chronic Kidney Disease
- First Posted Date
- 2022-07-15
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Vifor (International) Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT05460234
- Locations
- 🇩🇪
Dialysepraxis Spandau - 01012, Berlin, Germany
🇩🇪Tagesklinik - Lehrpraxis der Charité Dialyse - Apherese -01007, Berlin, Germany
🇩🇪Nierenzentrum Eichstätt MVZ GmbH - 01072, Eichstätt, Germany
Bioavailability Study Comparing 2 Vamifeport Oral Formulations in Fasted Versus Fed State in Healthy Subjects
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2021-10-14
- Last Posted Date
- 2022-08-17
- Lead Sponsor
- Vifor (International) Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT05077436
- Locations
- 🇬🇧
Labcorp Clinical Research Unit Ltd., Leeds, United Kingdom
Efficacy and Safety Study of Multiple Doses of VIT-2763 in Adults With Transfusion-dependent Beta-thalassemia
- Conditions
- Beta-Thalassemia
- Interventions
- Drug: VIT-2763 120 mg BIDDrug: VIT-2763 60 mg QDDrug: VIT-2763 60 mg BIDDrug: Placebo
- First Posted Date
- 2021-06-24
- Last Posted Date
- 2022-11-10
- Lead Sponsor
- Vifor (International) Inc.
- Registration Number
- NCT04938635
- Locations
- 🇺🇸
Investigator site #710, Whittier, California, United States
🇧🇬Investigational site #804, Stara Zagora, Bulgaria
🇧🇬Investigational site #802, Plovdiv, Bulgaria
Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of Hyperkalaemia
- Conditions
- Heart FailureHyperkalemia
- First Posted Date
- 2021-04-29
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Vifor (International) Inc.
- Target Recruit Count
- 2636
- Registration Number
- NCT04864795
- Locations
- 🇺🇸
Innovative Research of West Florida, Inc., Clearwater, Florida, United States
🇺🇸Clearwater Cardiovascular and Interventional Consultants, Safety Harbor, Florida, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
Study to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With Sickle Cell Disease
- Conditions
- Sickle Cell Disease
- Interventions
- Drug: VIT-2763 120 mgDrug: VIT-2763 360 mgDrug: VIT-2763 240 mgDrug: Placebo BIDDrug: Placebo TID
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- Vifor (International) Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT04817670
- Locations
- 🇫🇷
Investigator Site 801, Colombes, France
🇫🇷Investigator Site 802, Lyon, France
🇱🇧Investigator Site 101, Baabda, Lebanon
Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Preliminary Efficacy of VIT-2763 in β-thalassaemia
- Conditions
- Beta-ThalassemiaNon-transfusion-dependent Thalassemia
- Interventions
- Drug: VIT-2763 once a day (QD)Drug: VIT-2763 twice a day (BID)Drug: Placebo
- First Posted Date
- 2020-04-28
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- Vifor (International) Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT04364269
- Locations
- 🇬🇷
Clinical Site #303, Thessaloniki, Greece
🇹🇭Clinical Site #502, Chiang Mai, Thailand
🇹🇭Clinical Site #503, Phitsanulok, Thailand
To Assess the Impact of Ferric Carboxymaltose Compared With Iron Sucrose in Chinese Subjects on Correcting Iron Deficiency Anaemia
- Conditions
- Iron Deficiency Anemia
- Interventions
- First Posted Date
- 2018-07-19
- Last Posted Date
- 2021-06-10
- Lead Sponsor
- Vifor (International) Inc.
- Target Recruit Count
- 371
- Registration Number
- NCT03591406
- Locations
- 🇨🇳
The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China
Study to Compare Ferric Carboxymaltose With Placebo in Patients With Acute Heart Failure and Iron Deficiency
- Conditions
- Heart FailureIron Deficiency
- Interventions
- Other: Normal saline 0.9%
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2021-06-18
- Lead Sponsor
- Vifor (International) Inc.
- Target Recruit Count
- 1132
- Registration Number
- NCT02937454
- Locations
- 🇸🇪
Skane University Hospital, Malmö, Sweden
🇦🇷Hospital Universitario Austral, Buenos Aires, Argentina
🇭🇷Clinical Hospital Center Rijeka, Rijeka, Croatia